{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:34:12Z","timestamp":1793644452002,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Da Integracao Internacional Da Lusofonia Afro Brasileira"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, metabolic therapies originally developed to treat systemic metabolic disorders have been investigated as potential therapeutic strategies for Metabolic dysfunction-associated steatohepatitis (MASH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to critically evaluate recent clinical evidence on emerging metabolic therapies, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors and incretin-based agents, examining their effects on hepatic and metabolic outcomes and, when available, histological endpoints, as well as safety in patients with MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of clinical studies evaluating metabolic therapies in patients with MASH or metabolically associated fatty liver disease was conducted. Randomized clinical trials and other relevant clinical studies investigating SGLT2 inhibitors, incretin-based therapies, and other emerging metabolic agents were included. Outcomes of interest comprised metabolic parameters, hepatic outcomes related to steatosis and disease activity, and histological endpoints when available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve clinical studies were included. In trials with histological endpoints, semaglutide achieved steatohepatitis resolution without worsening of fibrosis in 62.9% versus 34.3% with placebo in a phase 3 trial (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while a phase 2 trial reported NASH resolution in 59% versus 17% with placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), without significant fibrosis improvement (43% versus 33%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.48). Tirzepatide achieved MASH resolution without worsening of fibrosis in 44\u201362% of patients versus 10% with placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all doses), and fibrosis improvement in 51\u201355% versus 30%. Among SGLT2 inhibitors, dapagliflozin achieved MASH improvement without worsening of fibrosis in 53% versus 30% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), MASH resolution in 23% versus 8% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and fibrosis improvement in 45% versus 20% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Overall, metabolic therapies improved body weight, hepatic steatosis, glycemic parameters, and disease activity, but evidence for durable fibrosis regression and long-term liver-related outcomes remains heterogeneous.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Emerging metabolic therapies show promising effects on metabolic and hepatic outcomes in patients with MASH. Incretin-based therapies appear to exert particularly robust effects on body weight reduction and steatohepatitis resolution, whereas SGLT2 inhibitors may provide complementary metabolic, cardiometabolic, and hepatic benefits. Nevertheless, fibrosis-related effects remain less consistent across studies, and future trials with paired histological endpoints, longer follow-up, and clinically meaningful liver-related outcomes are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04095-7","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:54:48Z","timestamp":1781052888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-7584","authenticated-orcid":false,"given":"Artur Macedo","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Carolyne Venancio","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-7587","authenticated-orcid":false,"given":"Jos\u00e9 Erivelton Souza Maciel","family":"de Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1700-2225","authenticated-orcid":false,"given":"Rian Brito","family":"Teles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4095_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K et al (2025) Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. Diabetes Care v 48:1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care v"},{"issue":"2","key":"4095_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-Jarvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13(2):134\u2013148. https:\/\/doi.org\/10.1016\/S2213-8587(24)00318-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"4095_CR3","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.17305\/bb.2025.12203","volume":"25","author":"Q Ge","year":"2025","unstructured":"Ge Q et al (2025) Effect of SGLT2 inhibitors on liver fat content: a meta-analysis. Biomol Biomed 25(12):2647\u20132657. https:\/\/doi.org\/10.17305\/bb.2025.12203","journal-title":"Biomol Biomed"},{"key":"4095_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52603-5","volume":"14","author":"AMC Ong Lopez","year":"2024","unstructured":"Ong Lopez AMC, Pajimna JAT (2024) Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep 14:2122. https:\/\/doi.org\/10.1038\/s41598-024-52603-5","journal-title":"Sci Rep"},{"key":"4095_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836455","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol 13:836455. https:\/\/doi.org\/10.3389\/fendo.2022.836455","journal-title":"Front Endocrinol"},{"key":"4095_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-025-02098-6","volume":"25","author":"A Erfanifar","year":"2025","unstructured":"Erfanifar A et al (2025) Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial. BMC Endocr Disord 25:277. https:\/\/doi.org\/10.1186\/s12902-025-02098-6","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"4095_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"184","author":"H Jang","year":"2024","unstructured":"Jang H et al (2024) Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med 184(4):375\u2013383. https:\/\/doi.org\/10.1001\/jamainternmed.2023.8029","journal-title":"JAMA Intern Med"},{"key":"4095_CR8","doi-asserted-by":"publisher","first-page":"1102792","DOI":"10.3389\/fphar.2023.1102792","volume":"14","author":"Y GU","year":"2023","unstructured":"GU Y et al (2023) Comparative efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol v 14:1102792. https:\/\/doi.org\/10.3389\/fphar.2023.1102792","journal-title":"Front Pharmacol v"},{"issue":"21","key":"4095_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"4","key":"4095_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"12","key":"4095_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"6","key":"4095_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R et al (2023) Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8(6):511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"4095_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N et al (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol 77(3):607\u2013618. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003","journal-title":"J Hepatol"},{"issue":"10504","key":"4095_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M et al (2025) Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 406(10504):719\u2013730. https:\/\/doi.org\/10.1016\/S0140-6736(25)01073-6","journal-title":"Lancet"},{"issue":"3","key":"4095_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70206","volume":"18","author":"J Lin","year":"2026","unstructured":"Lin J et al (2026) Sodium-glucose cotransporter 2 inhibitors for metabolic dysfunction-associated steatohepatitis. J Diabetes 18(3):e70206. https:\/\/doi.org\/10.1111\/1753-0407.70206","journal-title":"J Diabetes"},{"key":"4095_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081820","volume":"388","author":"Y Liu","year":"2025","unstructured":"Liu Y et al (2025) Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial. BMJ 388:e081820. https:\/\/doi.org\/10.1136\/bmj-2024-081820","journal-title":"BMJ"},{"key":"4095_CR17","doi-asserted-by":"publisher","unstructured":"Wang D et al (2024) Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure. Research Square, Preprint, rs.3.rs-4132581. https:\/\/doi.org\/10.21203\/rs.3.rs-4132581\/v1","DOI":"10.21203\/rs.3.rs-4132581\/v1"},{"issue":"10","key":"4095_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","volume":"148","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA et al (2023) Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation 148(10):834\u2013844. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065134","journal-title":"Circulation"},{"issue":"4","key":"4095_CR19","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.16198","volume":"27","author":"K Hirayama","year":"2025","unstructured":"Hirayama K et al (2025) Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: sub-analysis of a randomized controlled study. Diabetes Obes Metab 27(4):2059\u20132069. https:\/\/doi.org\/10.1111\/dom.16198","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4095_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.16043","volume":"27","author":"N Ao","year":"2025","unstructured":"Ao N, Du J, Jin S, Suo L, Yang J (2025) The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease. Diabetes Obes Metab 27(2):457\u2013467. https:\/\/doi.org\/10.1111\/dom.16043","journal-title":"Diabetes Obes Metab"},{"key":"4095_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09464-3","author":"W Zhang","year":"2025","unstructured":"Zhang W, Hu H (2025) The emerging therapeutic promise of SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease. Dig Dis Sci. https:\/\/doi.org\/10.1007\/s10620-025-09464-3","journal-title":"Dig Dis Sci"},{"key":"4095_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ 389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735","journal-title":"BMJ"},{"issue":"2","key":"4095_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70490","volume":"46","author":"DH Kim","year":"2026","unstructured":"Kim DH et al (2026) SGLT-2 inhibitors are associated with lower mortality and decompensation in patients with MASH cirrhosis and type 2 diabetes. Liver Int 46(2):e70490. https:\/\/doi.org\/10.1111\/liv.70490","journal-title":"Liver Int"},{"issue":"12","key":"4095_CR24","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","volume":"73","author":"X Mao","year":"2024","unstructured":"Mao X et al (2024) Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut 73(12):2054\u20132061. https:\/\/doi.org\/10.1136\/gutjnl-2024-332481","journal-title":"Gut"},{"issue":"1","key":"4095_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.amjmed.2025.06.039","volume":"139","author":"HN Pham","year":"2026","unstructured":"Pham HN et al (2026) SGLT2 inhibitors and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease: a real-world retrospective cohort study. Am J Med 139(1):57-65.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2025.06.039","journal-title":"Am J Med"},{"issue":"1","key":"4095_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/dom.70187","volume":"28","author":"M Banerjee","year":"2026","unstructured":"Banerjee M, Pal R, Pal S (2026) Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: a network meta-analysis. Diabetes Obes Metab 28(1):287\u2013295. https:\/\/doi.org\/10.1111\/dom.70187","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4095_CR27","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"4095_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70492","author":"A Belancic","year":"2026","unstructured":"Belancic A et al (2026) Comparative efficacy of GLP-1 receptor agonists, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: a network meta-analysis. Br J Clin Pharmacol. https:\/\/doi.org\/10.1002\/bcp.70492","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04095-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04095-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:29Z","timestamp":1783929449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04095-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4095"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04095-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}